DEPLOYDatabase

Company

EndoQuest Robotics

Houston-based endoluminal robotic surgery company.

HQ
Houston, TX

CategorySurgical robots

Overview

Houston-based endoluminal robotic surgery company. CEO Eduardo Fonseca. Endoluminal Surgical (ELS) System — flexible robot for scar-free procedures through natural orifices. PARADIGM Trial: FDA-approved final stage (Jan 2026), 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA). First robotic ESD by gastroenterologist in IDE trial (Oct 2025). Series D-2 co-led by Crescent Enterprises + Dr. Fred Moll (Intuitive Surgical co-founder). NVIDIA IGX Thor integration for AI vision. $176M total raised.

Verified record

Verified deployments
1 deployment on file
Active incidents
None on file

Key facts

Product

Endoluminal Surgical (ELS) System — flexible endoluminal robot

Trial

PARADIGM — FDA IDE, 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA)

FDA Status

Final stage approved (Jan 2026). First robotic ESD by gastroenterologist (Oct 2025).

Partnership

NVIDIA IGX Thor integration for AI-powered vision

CEO

Eduardo Fonseca

Data & sources

Web sources

3

3 sources backing this record.View all →

Safety record

No incidents on record for EndoQuest Robotics.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Operated deployments (1)

Operator customers (1)